Testing blood markers after a bone marrow donor transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial checks how certain blood “biomarkers” change after you receive donor stem cells to rebuild your blood and immune system. The goal is to learn whether these markers can better predict your immune recovery after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18 or older).
- You have a blood cancer (a malignant hemopathy).
- Your doctors recommend an allogeneic bone marrow (stem cell) transplant from a donor.
- You agree to join the study by signing consent.
- You are covered by your local social security/health coverage plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how certain proteins in the blood around the time of a stem cell transplant may differ based on your blood disease and the type of donor you have. It aims to help doctors understand how to better support patients during stem cell transplants.
This study looks at blood tests before and after a donor stem cell transplant to see if certain markers can predict early complications. If you are planning this type of transplant, your participation could help doctors better manage side effects.
This study measures certain immune cells in your blood after a stem cell transplant for acute myeloid leukemia (AML). It aims to understand how well your immune system recovers and may help predict how you'll do after transplant.
This trial looks at two blood markers to predict the risk of acute graft-versus-host disease after an allogeneic stem cell transplant. If you qualify, your care team may use results to help anticipate and manage complications earlier.
This study uses a simple blood or cheek swab test to look for early signs that AML or MDS might come back after a stem cell transplant. It may help doctors adjust treatment sooner.
This study tests whether giving specially treated donor immune cells after a stem cell transplant can help prevent relapse in patients with high-risk blood cancers. You would get a stem cell transplant from a relative, followed by an infusion of donor cells that have been processed to reduce the risk of graft-versus-host disease.
Hear when a new Malignant Hemopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.